Literature DB >> 6310053

Beta-adrenoreceptor mechanisms in essential tremor; a double-blind placebo controlled trial of metoprolol, sotalol and atenolol.

P N Leigh, D Jefferson, A Twomey, C D Marsden.   

Abstract

In order to elucidate the mode of action of beta-adrenoreceptor antagonists in essential tremor, the efficacy of chronic oral administration of metoprolol, atenolol and sotalol was compared in a randomised, double-blind placebo controlled trial in twenty-four patients. Only sotalol proved superior to placebo on both subjective and "objective" assessments. Metoprolol and sotalol produced comparable degrees of beta-adrenoreceptor antagonism as judged by the blockade of standing tachycardia. Atenolol, in the dose used, produced a trend towards a greater cardiac chronotropic effect. These findings provide no support for the concept that central or peripheral beta 1-adrenoreceptor mechanisms are important in essential tremor. The beneficial effect of beta-adrenoreceptor antagonists may be mediated predominantly through peripheral beta 2-adrenoreceptor mechanisms.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6310053      PMCID: PMC1027523          DOI: 10.1136/jnnp.46.8.710

Source DB:  PubMed          Journal:  J Neurol Neurosurg Psychiatry        ISSN: 0022-3050            Impact factor:   10.154


  18 in total

1.  Suppression of essential tremor by propranolol: correlation of effect with drug plasma levels and intensity of beta-adrenergic blockade.

Authors:  R G McAllister; W R Markesbery; R W Ware; S M Howell
Journal:  Ann Neurol       Date:  1977-02       Impact factor: 10.422

2.  Metoprolol for essential tremor.

Authors:  C W Britt; B H Peters
Journal:  N Engl J Med       Date:  1979-08-09       Impact factor: 91.245

3.  Effect of the beta adrenergic blocking agent propranolol on essential tremor.

Authors:  M H Morgan; R L Hewer; R Cooper
Journal:  J Neurol Neurosurg Psychiatry       Date:  1973-08       Impact factor: 10.154

4.  Metoprolol in essential tremor.

Authors:  O Ljung
Journal:  Lancet       Date:  1980-05-10       Impact factor: 79.321

5.  beta-Adrenoreceptor antagonists in essential tremor.

Authors:  D Jefferson; P Jenner; C D Marsden
Journal:  J Neurol Neurosurg Psychiatry       Date:  1979-10       Impact factor: 10.154

6.  Metoprolol tartrate for essential tremor.

Authors:  T Riley; A B Pleet
Journal:  N Engl J Med       Date:  1979-09-20       Impact factor: 91.245

7.  Treatment of essential tremor with metoprolol.

Authors:  O Ljung
Journal:  N Engl J Med       Date:  1979-11-01       Impact factor: 91.245

8.  Comparison between the acute hemodynamic effects and brain penetration of atenolol and metoprolol.

Authors:  P A van Zwieten; P B Timmermans
Journal:  J Cardiovasc Pharmacol       Date:  1979 Jan-Feb       Impact factor: 3.105

9.  Comparative antihypertensive effects and tissue distribution of beta adrenergic blocking drugs.

Authors:  H L Garvey; N Ram
Journal:  J Pharmacol Exp Ther       Date:  1975-07       Impact factor: 4.030

10.  Beta-adrenergic mechanisms in action tremor.

Authors:  R R Young; J H Growdon; B T Shahani
Journal:  N Engl J Med       Date:  1975-11-06       Impact factor: 91.245

View more
  22 in total

Review 1.  Essential tremor.

Authors:  Joaquim Jos Ferreira; Cristina Sampaio
Journal:  BMJ Clin Evid       Date:  2007-05-01

Review 2.  Pharmacotherapy of essential tremor : an overview of existing and upcoming agents.

Authors:  Kelly E Lyons; Rajesh Pahwa
Journal:  CNS Drugs       Date:  2008       Impact factor: 5.749

Review 3.  Current Opinions and Consensus for Studying Tremor in Animal Models.

Authors:  Sheng-Han Kuo; Elan D Louis; Phyllis L Faust; Adrian Handforth; Su-Youne Chang; Billur Avlar; Eric J Lang; Ming-Kai Pan; Lauren N Miterko; Amanda M Brown; Roy V Sillitoe; Collin J Anderson; Stefan M Pulst; Martin J Gallagher; Kyle A Lyman; Dane M Chetkovich; Lorraine N Clark; Murni Tio; Eng-King Tan; Rodger J Elble
Journal:  Cerebellum       Date:  2019-12       Impact factor: 3.847

4.  Beta-adrenoreceptor mechanisms in essential tremor: a comparative single dose study of the effect of a non-selective and a beta-2 selective adrenoreceptor antagonist.

Authors:  L Cleeves; L J Findley
Journal:  J Neurol Neurosurg Psychiatry       Date:  1984-09       Impact factor: 10.154

5.  The comparative effects of ICI 118551 and propranolol on essential tremor.

Authors:  D Jefferson; H J Wharrad; A T Birmingham; J M Patrick
Journal:  Br J Clin Pharmacol       Date:  1987-12       Impact factor: 4.335

Review 6.  Sotalol. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use.

Authors:  B N Singh; P Deedwania; K Nademanee; A Ward; E M Sorkin
Journal:  Drugs       Date:  1987-09       Impact factor: 9.546

7.  The tremorolytic action of beta-adrenoceptor blockers in essential, physiological and isoprenaline-induced tremor is mediated by beta-adrenoceptors located in a deep peripheral compartment.

Authors:  B Abila; J F Wilson; R W Marshall; A Richens
Journal:  Br J Clin Pharmacol       Date:  1985-10       Impact factor: 4.335

8.  Overview of essential tremor.

Authors:  Theresa A Zesiewicz; Abinaya Chari; Israt Jahan; Amber M Miller; Kelly L Sullivan
Journal:  Neuropsychiatr Dis Treat       Date:  2010-09-07       Impact factor: 2.570

Review 9.  Treatment of essential tremor: a systematic review of evidence and recommendations from the Italian Movement Disorders Association.

Authors:  Mario Zappia; Alberto Albanese; Elisa Bruno; Carlo Colosimo; Graziella Filippini; Paolo Martinelli; Alessandra Nicoletti; Graziella Quattrocchi; Giovanni Abbruzzese; Alfredo Berardelli; Roberta Allegra; Maria Stella Aniello; Antonio E Elia; Davide Martino; Daniela Murgia; Marina Picillo; Giovanna Squintani
Journal:  J Neurol       Date:  2012-08-11       Impact factor: 4.849

10.  Effect on finger tremor of withdrawal of long-term treatment with propranolol or atenolol.

Authors:  H J Wharrad; A T Birmingham; C G Wilson; E J Williams; J M Roland
Journal:  Br J Clin Pharmacol       Date:  1984-09       Impact factor: 4.335

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.